Annual report pursuant to Section 13 and 15(d)

Stock Grants

Stock Grants	12 Months Ended
Dec. 31, 2019
Equity [Abstract]
Stock Grants	NOTE 11 – STOCK GRANTS Director stock grants During the years December 31, 2019 and 2018, the Company granted its independent directors an aggregate of 11,054 and 6,725, respectively, shares of restricted common stock in the Company. These shares were fully vested upon issuance. The increase in number of shares issued was due to the expansion of the Board of Directors by two members effective June 1, 2018. The expense recognized for these grants based on the grant date fair value was $350,000 and $287,500 for the years ended December 31, 2019 and 2018, respectively. Consultant stock grants On April 10, 2017, the Company granted a consultant 500 shares of restricted common stock valued at $46 per share. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on April 1, 2017. The Company recognized $0 and $5,750 in stock-based compensation related to this grant during the years ended December 31, 2019 and 2018, respectively. On August 8, 2017, the Company granted a consultant 500 shares of restricted common stock valued at $35 per share. These shares were subject to a risk of forfeiture and vested 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017. The Company recognized $0 and $4,375 in stock-based compensation related to this grant during the years ended December 31, 2019 and 2018, respectively. On December 31, 2018, the Company granted consultants 563 shares of restricted common stock valued at $40 per share. These shares were fully vested upon issuance. The Company recognized $22,500 in stock-based compensation related to these grants during the year ended December 31, 2018. On March 31, 2019, the Company granted consultants 187 shares of restricted common stock valued at $34 per share. On June 30, 2019, the Company granted consultants 188 shares of restricted common stock valued at $25 per share. On September 30, 2019, the Company granted consultants 187 shares of restricted common stock valued at $17.80 per share. On December 31, 2019, the Company granted consultants 188 shares of restricted common stock valued at $12 per share. These shares were fully vested upon issuance. The Company recognized $16,650 in stock-based compensation related to these grants during the year ended December 31, 2019.

Stock Grants

12 Months Ended

Dec. 31, 2019

NOTE 11 – STOCK GRANTS

Director stock grants

During the years December 31, 2019 and 2018, the Company granted its independent directors an aggregate of 11,054 and 6,725, respectively, shares of restricted common stock in the Company. These shares were fully vested upon issuance. The increase in number of shares issued was due to the expansion of the Board of Directors by two members effective June 1, 2018. The expense recognized for these grants based on the grant date fair value was $350,000 and $287,500 for the years ended December 31, 2019 and 2018, respectively.

Consultant stock grants

On April 10, 2017, the Company granted a consultant 500 shares of restricted common stock valued at $46 per share. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on April 1, 2017. The Company recognized $0 and $5,750 in stock-based compensation related to this grant during the years ended December 31, 2019 and 2018, respectively.

On August 8, 2017, the Company granted a consultant 500 shares of restricted common stock valued at $35 per share. These shares were subject to a risk of forfeiture and vested 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017. The Company recognized $0 and $4,375 in stock-based compensation related to this grant during the years ended December 31, 2019 and 2018, respectively.

On December 31, 2018, the Company granted consultants 563 shares of restricted common stock valued at $40 per share. These shares were fully vested upon issuance. The Company recognized $22,500 in stock-based compensation related to these grants during the year ended December 31, 2018.

On March 31, 2019, the Company granted consultants 187 shares of restricted common stock valued at $34 per share. On June 30, 2019, the Company granted consultants 188 shares of restricted common stock valued at $25 per share. On September 30, 2019, the Company granted consultants 187 shares of restricted common stock valued at $17.80 per share. On December 31, 2019, the Company granted consultants 188 shares of restricted common stock valued at $12 per share. These shares were fully vested upon issuance. The Company recognized $16,650 in stock-based compensation related to these grants during the year ended December 31, 2019.